Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis

Brain Dev. Sep-Oct 1993;15(5):346-55. doi: 10.1016/0387-7604(93)90120-w.

Abstract

Eighteen patients, 16 boys and 2 girls, aged 5-14 years, with subacute sclerosing panencephalitis (SSPE) were treated with oral isoprinosine (100 mg/kg/day) and intraventricular alpha-interferon 2b (Intron A, Schering Corp.), starting at 500,000 U twice a week and later increasing to 3 million U biweekly. Minimal follow-up of living patients is 12 months; maximal 40 months. On the basis of the Neurological Disability Index (NDI) scores and staging, 8 have treatment-induced remissions (3 improved, 5 arrested), 4 are worse and 6 died. This 44% (8/18) rate of remission/improvement compares well with the 9% (1/11) remission in historical controls in the same institution (p = < 0.05) and 5% spontaneous remission in the literature. Combined oral isoprinosine-intraventricular alpha-interferon appears to be an effective treatment for SSPE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Child
  • Child, Preschool
  • Drug Therapy, Combination
  • Electroencephalography
  • Female
  • Humans
  • Injections, Intraventricular
  • Inosine Pranobex / administration & dosage
  • Inosine Pranobex / therapeutic use*
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Magnetic Resonance Imaging
  • Male
  • Recombinant Proteins
  • Subacute Sclerosing Panencephalitis / diagnostic imaging
  • Subacute Sclerosing Panencephalitis / drug therapy*
  • Subacute Sclerosing Panencephalitis / pathology
  • Tomography, X-Ray Computed

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Inosine Pranobex